Developing anti-neoplastic biotherapeutics against eIF4F

作者：Steinberger Jutta; Chu Jennifer; Maiga Rayelle Itoua; Sleiman Katia; Pelletier Jerry^*

来源：Cellular and Molecular Life Sciences, 2017, 74(9): 1681-1692.

DOI：10.1007/s00018-016-2430-8

• Biotherapeutics
• eIF4F
• eIF4A
• 4EBP
• PDCD4
• Translational control
• Antisense
• Cancer therapeutics

Biotherapeutics have revolutionized modern medicine by providing medicines that would not have been possible with small molecules. With respect to cancer therapies, this represents the current sector of the pharmaceutical industry having the largest therapeutic impact, as exemplified by the development of recombinant antibodies and cell-based therapies. In cancer, one of the most common regulatory alterations is the perturbation of translational control. Among these, changes in eukaryotic initiation factor 4F (eIF4F) are associated with tumor initiation, progression, and drug resistance in a number of settings. This, coupled with the fact that systemic suppression of eIF4F appears well tolerated, indicates that therapeutic agents targeting eIF4F hold much therapeutic potential. Here, we discuss opportunities offered by biologicals for this purpose.

• 出版日期2017-5
• 单位McGill